



### **Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series**

CAMBRIDGE, Mass., September 20, 2017 -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the LEERINK Partners Roundtable Series: Rare Disease and Immuno-Oncology on Wednesday, September 27, 2017 at 11:00 a.m. ET. The conference will be held at the Lotte New York Palace in New York City.

A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at [www.dicerna.com](http://www.dicerna.com). An archived replay of the webcast will be available on the Company's website after the conference.

#### **About Dicerna Pharmaceuticals, Inc.**

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

#### **Investor Contact:**

Rx Communications Group  
Paula Schwartz, 917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

#### **Media Contact:**

SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)